Tag:

Eli Lilly

Latest Headlines

Latest Headlines

Eli Lilly scores a multibillion-dollar win in Alimta's EU patent fight

Eli Lilly scored a victory in its patent battle for lung cancer blockbuster Alimta in Europe, as the Court of Appeal in London ruled against Actavis' plan to market copycat versions of the med.

London mayor moots £10B biotech 'megafund' to close gap on U.S. hotspots

The mayor of London has come up with a scheme to bridge the financial chasm between the U.K. and U.S. biotech hubs. Officials have called Eli Lilly, Pfizer and JP Morgan to a meeting to discuss the plan, which entails creating a £10 billion ($15 billion) fund to invest in drugs across the development spectrum, The Financial Times reports.

Lilly and Teva tout new migraine data amid a crowded race

Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.

Novartis zeroes in on costs as blockbusters-to-be Cosentyx, Entresto rev up

Novartis has had a complicated year: Three months ago, the Swiss drugmaker closed its multipart asset swap with GlaxoSmithKline, sending most of its troubled vaccines business to GSK and taking on the U.K. drugmaker's oncology business.

Lilly calls in some academic muscle to get its cancer pipeline moving

Eli Lilly inked a pair of deals with Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute to hit the gas on oncology R&D, aiming to shorten the development process for a slew of new medicines.

Japan's PAFSC backs Lilly's dulaglutide, among others, in latest round

Eli Lilly Japan's once-weekly glucagon-like peptide-1 receptor agonist dulaglutide was recommended for approval by Japan's Pharmaceutical Affairs and Food Sanitation Council's (PAFSC's) First Committee on Drugs, an advisory panel to the health minister, following a June 5 meeting, an official said.

Is Lilly on the verge of an Alzheimer's turnaround?

Some early-stage success for Biogen has inaugurated something of a second honeymoon for a class of investigational Alzheimer's disease treatments, and some investors believe Eli Lilly, maker of a similar therapy, could be poised to reverse its bleak fortunes in the field.

Lilly quashes rumors of Elanco spinoff as stock soars

Eli Lilly's stock was on a tear June 9, advancing more than any other stock in the Standard & Poor's 500 Index, after investors surmised the company might be planning to spin off its animal health unit, Elanco. The rumor--which Lilly quickly tried to quiet--originally started spreading after Elanco's president, Jeffrey Simmons, spoke at a Goldman Sachs investment conference.

ADA highlights: Novo, Lilly meds top Lantus; Sanofi, AZ tout new combo regimens

The data pump is going full tilt at the American Diabetes Association meeting, with top drugmakers rolling out studies on their top drugs, new and old. From new safety analyses to head-to-head match-ups, here's a roundup of the need-to-know.

Lilly's latest lung cancer contender lines up for FDA scrutiny

Eli Lilly, angling for FDA approval for its newest lung cancer treatment, has a July 9 date with a panel of independent agency advisers, a crucial hurdle in the regulatory process.